7月17日，CRO指数上涨3%，成都先导涨停，博济医药上涨16%，泓博医药、睿智医药、药石科技跟涨。药明康德发布2025年半年报预增预告，预计归母净利润同比增长约101.9%，带动CRO行业整体走强。随着全球投融资逐步恢复，海外有望逐步进入降息节奏，投融资改善预期有望边际向好，一体化CRO/CDMO及国内临床前CRO有望迎来估值修复机会。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.